In the original article, there was a mistake in Table 1 as published. BZBS is a post-marketing drug, and there is an error in the components of BZBS and ratio amounts in application (Li et al., 2021). The corrected Table 1 appears below.
TABLE 1
| Plants | Amount in application (ratio) |
|---|---|
| Cuscuta chinensis Lam. [Convolvulaceae; Cuscutae semen] | 250 |
| Lycium barbarum L. [Solanaceae; Lycii cortex] | 138 |
| Schisandra chinensis (Turcz.) Baill. [Schisandraceae; Schisandrae chinensis fructus] | 46 |
| Cnidium monnieri (L.) Cusson [Apiaceae; Cnidii fructus] | 35 |
| Rosa laevigata Michx. [Rosaceae; Rosae laevigatae fructus] | 35 |
| Rubus chingii Hu [Rosaceae; Rubi fructus] | 35 |
| Allium tuberosum Rottler ex Spreng. [Amaryllidaceae; Allii tuberosi semen] | 35 |
| Toosendan fructus [Meliaceae; Fuctus Toosendan] | 23 |
| Epimedium brevicornu Maxim. [ Berberidaceae; Epimedii folium] | 70 |
| Morindae officinalis radix [Rubiaceae; Radix Morindae Offcinalis] | 35 |
| Cistanche deserticola Ma [Orobanchaceae; Cistanches herba] | 35 |
| Rehmannia root [Orobanchaceae; Radix Rehmanniae Recens] | 46 |
| Cyathula officinalis K.C.Kuan [Amaranthaceae; Cyathulae radix] | 35 |
| Panax ginseng C.A.Mey. [Araliaceae; Ginseng radix et rhizoma] | 25 |
| Cervus nippon Temminck [Cervidae; Cervi Cornu Pantotrichum] | 16 |
| Hippocampus Kelloggi [Syngnathidae; Hippocampus] | 21 |
The ratio of the plants present in the preparation of BZBS.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
LiL.ChenB.AnT.ZhangH.XiaB.LiR.et al (2021). BaZiBuShen Alleviates Altered Testicular Morphology and Spermatogenesis and Modulates Sirt6/P53 and Sirt6/NF-Κb Pathways in Aging Mice Induced by D-Galactose and NaNO2. J. Ethnopharmacol271, 113810. 10.1016/j.jep.2021.113810
Summary
Keywords
atherosclerosis, bazi bushen capsule, lipid profile, inflammation, GPER1 antagonist, apoptosis
Citation
Huang D, Wang X, Zhu Y, Gong J, Liang J, Song Y, Zhang Y, Liu L and Wei C (2021) Corrigendum: Bazi Bushen Capsule Alleviates Post-Menopausal Atherosclerosis via GPER1-Dependent Anti-Inflammatory and Anti-Apoptotic Effects. Front. Pharmacol. 12:774792. doi: 10.3389/fphar.2021.774792
Received
13 September 2021
Accepted
17 September 2021
Published
04 October 2021
Volume
12 - 2021
Edited and reviewed by
Hongzhi Du, Hubei University of Chinese Medicine, China
Updates
Copyright
© 2021 Huang, Wang, Zhu, Gong, Liang, Song, Zhang, Liu and Wei.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Linsheng Liu, linsheng_liu@126.com; Cong Wei, weicong@yiling.cn
†These authors have contributed equally to this work
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.